314 related articles for article (PubMed ID: 16280285)
1. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
[TBL] [Abstract][Full Text] [Related]
3. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Devroey D; Velkeniers B; Duquet W; Betz W
Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
[TBL] [Abstract][Full Text] [Related]
5. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
7. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
9. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
Spring S; Simon R; van der Loo B; Kovacevic T; Brockes C; Rousson V; Amann-Vesti B; Koppensteiner R
Thromb Haemost; 2008 Jan; 99(1):182-9. PubMed ID: 18217152
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Bruckert E; De Gennes JL; Malbecq W; Baigts F
Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
[TBL] [Abstract][Full Text] [Related]
11. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
12. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
[TBL] [Abstract][Full Text] [Related]
13. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.
de Sauvage Nolting PR; de Groot E; Zwinderman AH; Buirma RJ; Trip MD; Kastelein JJ
Arch Intern Med; 2003 Aug 11-25; 163(15):1837-41. PubMed ID: 12912721
[TBL] [Abstract][Full Text] [Related]
14. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
15. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
17. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Freeman SR; Drake AL; Heilig LF; Graber M; McNealy K; Schilling LM; Dellavalle RP
J Natl Cancer Inst; 2006 Nov; 98(21):1538-46. PubMed ID: 17077356
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
[TBL] [Abstract][Full Text] [Related]
20. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
